Abciximab: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) m (→Overview) |
||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
'''Abciximab''' (previously known as '''c7E3 Fab'''), a [[glycoprotein IIb/IIIa]] receptor antagonist manufactured by [[Janssen Biologics BV]] and distributed by [[Eli Lilly and Company|Eli Lilly]] under the trade name '''ReoPro''', is a [[platelet aggregation inhibitor]] mainly used during and after [[coronary artery]] procedures like [[angioplasty]] to prevent [[platelet]]s from sticking together and causing thrombus ([[blood clot]]) formation within the coronary artery. It is a [[glycoprotein IIb/IIIa inhibitor]].<ref>{{cite web|url=http://www.drugs.com/cdi/abciximab.html|title=Abciximab|work=Drugs.com|accessdate=13 March 2010| archiveurl= http://web.archive.org/web/20100420014357/http://www.drugs.com/cdi/abciximab.html| archivedate= 20 April 2010 <!--DASHBot-->| deadurl= no}}</ref> | |||
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the [[platelet]]s, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug.(Tanguay, J.F., Eur Heart J 1999; 1 (suppl E): E27-E35 | |||
Abciximab is made from the [[Fragment antigen binding|Fab]] fragments of an [[immunoglobulin]] that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.<ref name="INN">{{cite journal|url=http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf|journal=WHO Drug Information|volume=7|issue=4|title=International Nonproprietary Names for Pharmaceutiical Substances|year=1993}}</ref> | |||
==Category== | ==Category== | ||
Revision as of 19:27, 29 January 2014
Template:Abciximab Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here.
Overview
Abciximab (previously known as c7E3 Fab), a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[1]
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug.(Tanguay, J.F., Eur Heart J 1999; 1 (suppl E): E27-E35 Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.[2]
Category
US Brand Names
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ "Abciximab". Drugs.com. Archived from the original on 20 April 2010. Retrieved 13 March 2010.
- ↑ "International Nonproprietary Names for Pharmaceutiical Substances" (PDF). WHO Drug Information. 7 (4). 1993.